Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Manito Lorite, Nicolás
- dc.contributor.author Cepeda Rodrigo, José María
- dc.contributor.author Farré López, Núria
- dc.contributor.author Castillo Orive, Miguel
- dc.contributor.author Galve, Enrique
- dc.contributor.author Jiménez Candil, Javier
- dc.contributor.author García Pinilla, José M.
- dc.contributor.author López Sánchez, Eduardo Sebastián
- dc.contributor.author Rafols, Carles
- dc.contributor.author Gómez Doblas, Juan José
- dc.date.accessioned 2024-10-09T06:25:04Z
- dc.date.available 2024-10-09T06:25:04Z
- dc.date.issued 2024
- dc.description.abstract Background: Patients with atrial fibrillation (AF) and heart failure (HF) have a high risk of thromboembolism and other outcomes and anticoagulation is recommended. Hypothesis: This study was aimed to explore the risk factors associated with HF worsening in patients with AF and HF taking rivaroxaban in Spain. Methods: Multicenter, prospective, observational study that included adults with AF and chronic HF, receiving rivaroxaban ≥4 months before entering. HF worsening was defined as first hospitalization or emergency visit because of HF exacerbation. Results: A total of 672 patients from 71 Spanish centers were recruited, of whom 658 (97.9%) were included in the safety analysis and 552 (82.1%) in the per protocol analysis. At baseline, mean age was 73.7 ± 10.9 years, 64.9% were male, CHA2 DS2 -VASc was 4.1 ± 1.5, HAS-BLED was 1.6 ± 0.9% and 51.3% had HF with preserved ejection fraction. After 24 months of follow-up, 24.9% of patients developed HF worsening, 11.6% died, 2.9% had a thromboembolic event, 3.1% a major bleeding, 0.5% an intracranial bleeding and no patient had a fatal hemorrhage. Older age, the history of chronic obstructive pulmonary disease, the previous use of vitamin K antagonists, and restrictive or infiltrative cardiomyopathies, were independently associated with HF worsening. Only 6.9% of patients permanently discontinued rivaroxaban treatment. Conclusions: Approximately one out of four patients with HF and AF treated with rivaroxaban developed a HF worsening episode after 2 years of follow-up. The identification of those factors that increase the risk of HF worsening could be helpful in the comprehensive management of this population.
- dc.format.mimetype application/pdf
- dc.identifier.citation Manito N, Cepeda-Rodrigo JM, Farré N, Castillo Orive M, Galve E, Jiménez-Candil J, et al. Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban. Clin Cardiol. 2024 Feb;47(2):e24189. DOI: 10.1002/clc.24189
- dc.identifier.doi http://dx.doi.org/10.1002/clc.24189
- dc.identifier.issn 0160-9289
- dc.identifier.uri http://hdl.handle.net/10230/61358
- dc.language.iso eng
- dc.publisher Wiley
- dc.relation.ispartof Clin Cardiol. 2024 Feb;47(2):e24189
- dc.rights © 2023 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Anticoagulation
- dc.subject.keyword Atrial fibrillation
- dc.subject.keyword Direct oral anticoagulant
- dc.subject.keyword Heart failure
- dc.subject.keyword Rivaroxaban
- dc.subject.keyword Worsening heart failure
- dc.title Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion